Literature DB >> 26018827

An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer.

Narendranath Epperla1, Ben George2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26018827     DOI: 10.1007/s12029-015-9735-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  42 in total

1.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.

Authors:  W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-11       Impact factor: 4.254

2.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

3.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

4.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Authors:  Carsten Bokemeyer; Eric Van Cutsem; Philippe Rougier; Fortunato Ciardiello; Steffen Heeger; Michael Schlichting; Ilhan Celik; Claus-Henning Köhne
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

Review 5.  Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis.

Authors:  Albert Y Lin; Nicholas S Buckley; An-Ting T Lu; Natalia B Kouzminova; Shelley R Salpeter
Journal:  Clin Colorectal Cancer       Date:  2011-03-01       Impact factor: 4.481

6.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

7.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.

Authors:  J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

9.  The prognostic value of KRAS mutations in patients with colorectal cancer.

Authors:  Yasuhiro Inoue; Susumu Saigusa; Takashi Iwata; Yoshinaga Okugawa; Yuji Toiyama; Koji Tanaka; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Oncol Rep       Date:  2012-08-21       Impact factor: 3.906

10.  Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Authors:  Sun Lee; Nam-Yun Cho; Minhee Choi; Eun J Yoo; Jung-Ho Kim; Gyeong H Kang
Journal:  Pathol Int       Date:  2008-02       Impact factor: 2.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.